<div id="readability-page-1"><p>Burgundy Asset Management Ltd. raised its position in  Globus Medical, Inc. (NYSE:GMED - Free Report) by 7.0% in the 1st quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor  owned 2,801,747 shares of the medical device company's stock after acquiring an additional 183,639 shares during the period. Globus Medical comprises approximately  2.1% of Burgundy Asset Management Ltd.'s holdings, making the stock its 8th largest holding. Burgundy Asset Management Ltd. owned 2.04% of Globus Medical worth $205,088,000 at the end of the most recent reporting period.</p><p>Other hedge funds have also modified their holdings of the company. Farther Finance Advisors LLC grew its position in  Globus Medical by 145.5% during the 1st quarter. Farther Finance Advisors LLC now owns 405 shares of the medical device company's stock worth $30,000 after acquiring an additional 240 shares during the last quarter.  Larson Financial Group LLC grew its position in  Globus Medical by 1,007.7% during the 1st quarter. Larson Financial Group LLC now owns 432 shares of the medical device company's stock worth $32,000 after acquiring an additional 393 shares during the last quarter.  Parallel Advisors LLC grew its position in  Globus Medical by 62.1% during the 1st quarter. Parallel Advisors LLC now owns 504 shares of the medical device company's stock worth $37,000 after acquiring an additional 193 shares during the last quarter.  Versant Capital Management Inc grew its position in  Globus Medical by 932.1% during the 1st quarter. Versant Capital Management Inc now owns 547 shares of the medical device company's stock worth $40,000 after acquiring an additional 494 shares during the last quarter.  Finally, Whittier Trust Co. grew its position in  Globus Medical by 46.5% during the 1st quarter. Whittier Trust Co. now owns 580 shares of the medical device company's stock worth $42,000 after acquiring an additional 184 shares during the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds. </p><div><p><span></span><span>Get <strong>Globus Medical</strong> alerts:</span></p></div><h2>Wall Street Analyst Weigh In</h2><p>GMED has been the topic of a number of research analyst reports. Canaccord Genuity Group decreased their price target on Globus Medical from $97.00 to $90.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, July 22nd. Barclays  reissued an &#34;overweight&#34; rating on shares of Globus Medical in a research note on Tuesday, June 10th. Morgan Stanley lowered their target price on Globus Medical from $75.00 to $68.00 and set an &#34;overweight&#34; rating for the company in a research note on Tuesday, July 15th. Truist Financial lowered their target price on Globus Medical from $80.00 to $68.00 and set a &#34;hold&#34; rating for the company in a research note on Monday, May 12th. Finally, Piper Sandler lowered their target price on Globus Medical from $100.00 to $80.00 and set an &#34;overweight&#34; rating for the company in a research note on Friday, May 9th. Five equities research analysts have rated the stock with a hold rating and nine have issued  a buy rating to the company. According to data from MarketBeat.com, the stock  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $87.64.</p><p><b>Get Our Latest Research Report on Globus Medical</b></p><h2>Globus Medical Trading Up 1.0%</h2><p>GMED stock opened at $60.63 on Friday. The business's 50-day moving average price is $57.22 and its two-hundred day moving average price is $67.33. The firm has a market cap of $8.21 billion, a PE ratio of 23.32, a P/E/G ratio of 1.68 and a beta of 1.20. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $94.93. </p><p>Globus Medical (NYSE:GMED - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical device company reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.76 by $0.10. The firm had revenue of $745.34 million for the quarter, compared to analyst estimates of $738.91 million. Globus Medical had a return on equity of 10.65% and a net margin of 13.58%. The company's revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.75 earnings per share.  On average, analysts forecast that  Globus Medical, Inc. will post 3.44 earnings per share for the current year. </p><p>Globus Medical announced that its board has initiated a stock buyback plan on Thursday, May 15th that permits the company to repurchase $500.00 million in  outstanding  shares. This repurchase authorization permits the medical device company to reacquire up to 6.3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its stock is undervalued. </p><h2>Globus Medical Profile</h2> (Free Report)<p>Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Globus Medical</li><li>When to Sell a Stock for Profit or Loss</li><li>3 Energy Stocks to Gain Exposure to the Carbon Capture Boom</li><li>Best Stocks Under $10.00 </li><li>AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple</li><li>How to Calculate Options Profits</li><li>The Real Reason Ford Stock Is Rallying—Can It Keep Going?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Globus Medical Right Now?</h2><p>Before you consider Globus Medical, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Globus Medical wasn't on the list.</p><p>While Globus Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GMED

<p>Burgundy Asset Management Ltd. increased its stake in Globus Medical, Inc. (NYSE:GMED) by 7.0% in Q1, now owning 2,801,747 shares. The stock represents 2.1% of Burgundy's holdings, valued at $205 million. Other hedge funds also raised their positions significantly. Analysts have mixed ratings, with a consensus of "Moderate Buy" and an average target price of $87.64. Globus Medical reported strong earnings, exceeding estimates, and announced a $500 million stock buyback plan.</p>

Globus Medical, Inc. (NYSE:GMED) Shares Purchased by Burgundy Asset Management Ltd.